Emergence agitation in adults: risk factors in 2,000 patients.
Daihua Yu, Wei Chai, Xude Sun...
https://pubmed.ncbi.nlm.nih.gov/20526708/Actively Recruiting
Led by Fayoum University Hospital · Updated on 2026-09-30
50
Participants Needed
1
Research Sites
4 weeks
Total Duration
This clinical trial investigates the effectiveness of two different dosing methods of dexmedetomidinea single bolus dose versus continuous infusionin reducing the occurrence of emergence agitation in obese adults undergoing nasal surgery. Emergence agitation is a complication during recovery from general anesthesia that can cause serious risks such as self-injury and complications related to extubation. The study focuses on adults with risk factors including obesity and ear, nose, and throat surgery, aiming to find the optimal way to prevent this condition. Participants receive routine general anesthesia with standard monitoring and medications. They will be randomly assigned to receive either a single dose of dexmedetomidine administered 15 minutes before the end of surgery or a continuous infusion of dexmedetomidine throughout the operation. Both administration methods are being evaluated for their impact on emergence agitation and related outcomes. Throughout the study, participants will be closely monitored during surgery and recovery. Assessments include measuring agitation levels shortly after surgery, heart rate, blood pressure, pain management, extubation time, and recovery duration. Safety measures such as monitoring for nausea, vomiting, bradycardia, and hypotension are also in place. The study period covers the surgery and postanesthesia care unit stay, with follow-up on analgesic use and other post-operative outcomes up to 24 hours after surgery.
CONDITIONS
Dexmedetomidine and Agitation After Nasal Surgery
Y
Yasser S Mostafa, MD
M
Mohamed A Shawky, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fayoum University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of surgery
Participants receive either a single dose of dexmedetomidine before the end of surgery or a continuous infusion during the operation. Standard anesthesia and monitoring are provided throughout surgery.
During surgery
Duration - Up to 24 hours after surgery
Participants are monitored in the postanesthesia care unit for agitation, heart rate, blood pressure, pain, and other recovery measures. Safety and recovery outcomes are tracked up to 24 hours after surgery.
Regular checks in postanesthesia care unit
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Daihua Yu, Wei Chai, Xude Sun...
https://pubmed.ncbi.nlm.nih.gov/20526708/Min Zhu, Haiyun Wang, Ai Zhu...
https://pubmed.ncbi.nlm.nih.gov/25874562/Kim Hudek
https://pubmed.ncbi.nlm.nih.gov/19326585/Hyo-Jin Kim, Duk-Kyung Kim, Hyo-Yeol Kim...
https://pubmed.ncbi.nlm.nih.gov/25729495/C Lepousé, C A Lautner, L Liu...
https://pubmed.ncbi.nlm.nih.gov/16670111/Fayoum University Hospital
Lead Sponsor